Quarterly ResultApr 23, 2026, 04:26 PM
Edwards Lifesciences Q1 Sales Up 16.7% to $1.65B
AI Summary
Edwards Lifesciences reported strong financial results for the first quarter of 2026. The company's total sales increased by 16.7% to $1.65 billion, with constant currency sales growing 12.7%. This growth was significantly driven by its Transcatheter Aortic Valve Replacement (TAVR) segment, which saw sales rise by 14.4% to $1.20 billion.
Key Highlights
- Q1 total sales grew 16.7% to $1.65 billion.
- Constant currency sales increased by 12.7%.
- Q1 TAVR sales rose 14.4% to $1.20 billion.
- TAVR constant currency sales grew 11.0%.